Preclinical studies show that CD4+ T cells mediate the crosstalk between CAR-T cells and the endogenous immune system, which is necessary for optimal CAR-T-cell efficacy to prevent tumor escape and improve long-term survival outcomes (9–11). Here, CD4 is linked to neoplasm.